Loading...
Loading...
Browse all stories on DeepNewz
VisitRegenxbio's RGX-202 Gene Therapy Shows Positive Results, FDA Approval Pathway Available
Nov 18, 2024, 12:34 PM
Regenxbio has reported promising results from its experimental gene therapy, RGX-202, for treating boys with Duchenne muscular dystrophy. The company presented clinical evidence showing improved muscle function in patients following the treatment. Regenxbio's CEO, Curran Simpson, indicated in an interview with STAT on Sunday that the FDA has communicated that the accelerated approval pathway remains available for this therapy. The positive data from a small trial is expected to support Regenxbio's pursuit of regulatory approval.
View original story
Markets
No • 50%
Yes • 50%
FDA's official announcements or press releases
No • 50%
Yes • 50%
Regenxbio's official press releases or clinical trial registries
Yes • 50%
No • 50%
Official announcements from Regenxbio or partner company
Less than 10% • 25%
More than 50% • 25%
25% to 50% • 25%
10% to 25% • 25%
Market analysis reports or industry publications
No Approval • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
FDA's official announcements or press releases
In 2026 • 25%
After 2026 • 25%
Before 2025 • 25%
In 2025 • 25%
Regenxbio's official announcements or market reports